# Gene Therapy Company News

If you are interested in the latest gene therapy company news, you've come to the right place. Our experts have gathered the latest on Bluebird Bio, GenBio, Novartis Gene Therapies, and other biotech companies that are advancing this field. Read on for the latest on these companies. There are many ways to keep updated on gene therapy company news. This article will focus on the companies that have made big headlines recently.

### GenBio

As the field of [gene therapy company news](http://www.allcrispr.com/) enters the next stage, GenBio is gearing up for an exciting future. With an existing manufacturing process that will allow it to develop therapies for a variety of conditions, the company now needs a facility that can help it put its large ambitions into action. In order to accomplish that goal, the company has signed a lease on a new 104,000 square foot facility in Waltham, Massachusetts. This facility is expected to be operational by 2023 and will support the company's preclinical and clinical development.

The company has already developed polypeptide-based materials that can act as effective vectors for gene therapies and may be customized to specific applications. This discovery could help the company develop treatments for hemophilia A and other rare conditions. Researchers have also developed a proof-of-concept treatment for a blood disorder that can raise hemoglobin levels. These trials could potentially pave the way for a larger, commercial-scale IPO.

### Krystal Biotech

The latest Krystal Biotech gene therapy company news is positive. The company is confident in its pipeline and recently broke ground on a new, 100,000-square-foot manufacturing facility. The facility, named Astra, will be a modular expansion of the company's existing Pittsburgh facility. When completed, it will employ up to 200 people. The company plans to begin commercializing its product in the second half of this year.

The Krystal Biotech gene therapy company's management team is confident in the company's ability to successfully commercialize its research. Although the company is still in its early stages, it is hoping to hit the public markets sooner rather than later. It has not hired a full-time CFO yet, and its seven-member team is heavily skewed towards research and development. This will allow the company to accelerate its clinical development.

### Novartis Gene Therapies

The company's new facility in Durham, North Carolina, will be more than 170,000 square feet and will produce a gene therapy product for clinical trials. The company is also expanding its existing plant in Libertyville, Illinois, to produce its gene therapy product Zolgensma, which is approved to treat spinal muscular atrophy. Ultimately, it hopes to expand its label on Zolgensma and develop other therapies.

In recent years, Novartis has made several acquisitions, including Vedere Bio Inc. for up to $280 million and Arctos Medical for an undisclosed amount. These companies are developing technologies to treat diseases, including inherited and inflammatory disorders. The company also acquired the privately held AveXis in 2018.

### Bluebird Bio

Shares of bluebird bio soared in late trading Friday following news that advisers to US drug regulators endorsed two of the company's gene therapies. The company's beti-cel treatment for beta thalassemia received an overwhelming 13-0 vote from the FDA's advisory committee, and its treatment for a child's brain wasting disease was also recommended. However, the FDA's recommendation does not necessarily mean the gene therapies will be approved.

Despite positive signs, the company has faced many setbacks in its quest to bring this therapy to market. The FDA, for instance, halted a clinical trial for the company's SCD therapy in February 2021 due to concerns over acute myeloid leukemia (AML). The company also burned through billions of dollars in investor money. As of FY21, its accumulated deficit was $3.72bn, which made the company look uninvestable at times. In addition, bluebird has faced a variety of setbacks in the European market, commercial failures and increasing competition from other CRISPR companies.

### Andson Biotech

Andson Biotech is a startup that was formed from a partnership between the National Science Foundation and Georgia Institute of Technology. The company has already received funding from the Georgia Research Alliance's Biolocity program, which allowed it to develop its technology with the help of MC3M and CMaT, two leading genome engineering companies. In addition to Biolocity, the company has formed collaborations with both organizations, including the Marcus Center for Therapeutic Cell Characterization and Manufacturing, to further develop its technology.

The company has also developed a new treatment for LGMD 2B, a severe form of epilepsy. It addresses a cellular deficit that causes the disease, and the therapy targets the NPSR1 gene. These developments represent a significant breakthrough for gene and cell therapy companies, and could be used to cure countless terminal illnesses. But gene and cell therapies have a number of challenges, including the complex analytical methods used by drug developers. These methods can be inefficient, slow, and inaccurate.